Vaccination Pfizer and BioNTech was 73.2% effective in inhibition Covid-19 Among children aged 6 months to 4 years, two months after starting to use the vaccine, new data from the institute showed this Tuesday (23). America For that age group.
The Pfizer-BioNTech vaccine was approved in the U.S. in June for children under 5, based on data showing the vaccine produces immunity similar to that of older adults.
Preliminary analysis based on ten symptomatic Covid-19 cases in the study suggested 80.3% vaccine efficacy. But experts cautioned that the data is preliminary due to the small number of symptomatic cases.
Updated data released Tuesday showed 13 children had Covid-19 at least seven days after receiving the third dose of the Pfizer-BioEntech vaccine, compared with 21 cases among those who received a placebo.
Pfizer and BioEntech also said they are preparing a US approval application for a so-called bivalent vaccine targeting Omicron’s BA.4/BA.5 subtypes for children under 12 years of age.
On Monday the companies applied for US approval of the bivalent vaccine to be given to people 12 years and older.
“Music geek. Coffee lover. Devoted food scholar. Web buff. Passionate internet guru.”